Clinical Trials Logo

Immune Checkpoint Inhibition clinical trials

View clinical trials related to Immune Checkpoint Inhibition.

Filter by:
  • None
  • Page 1

NCT ID: NCT04507750 Recruiting - Clinical trials for Immune Checkpoint Inhibition

Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer

Start date: August 10, 2020
Phase: N/A
Study type: Interventional

The aim of this study is to explore the effectiveness and safety of camrelizumab combined with apatinib mesylate in the treatment of relapsed platinum-resistant epithelial ovarian cancer

NCT ID: NCT03610711 Active, not recruiting - Clinical trials for Gastroesophageal Cancer

REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer

REACTION
Start date: March 6, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1B study assessing the safety of immune checkpoint inhibition after SBRT in patients with recurrent or metastatic gastroesophageal cancer (limited metastatic disease).